Clinical Scorecard: Mapping Carbon Hotspots in Pharma Supply Chains
At a Glance
| Category | Detail |
|---|---|
| Condition | Carbon emissions in pharmaceutical supply chains |
| Key Mechanisms | Life cycle assessment (LCA) and social network analysis (SNA) |
| Target Population | Pharmaceutical companies and supply chain stakeholders |
| Care Setting | Pharmaceutical supply chains |
Key Highlights
- Central players like logistics hubs significantly influence carbon footprints.
- The responsibility contribution index (RCI) ranks supply chain nodes by emissions and influence.
- Carbon emissions are concentrated along a few key pathways.
- Targeting high-emission, well-connected nodes can enhance decarbonization efforts.
- Network dynamics offer new strategies for sustainability in pharma.
Guideline-Based Recommendations
Diagnosis
- Assess carbon emissions across the entire supply chain using LCA.
Management
- Focus on nodes with high emissions and strong network influence for decarbonization.
Monitoring & Follow-up
- Utilize RCI to track emissions and influence of supply chain nodes.
Risks
- Overlooking low-emission nodes that control significant transport routes may hinder carbon reduction efforts.
Patient & Prescribing Data
Not applicable; relevant to pharmaceutical supply chain management.
Decarbonization strategies can lead to more sustainable drug production.
Clinical Best Practices
- Implement network-aware interventions for carbon reduction.
- Regularly evaluate supply chain nodes for emissions and structural influence.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
